The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFutura Medical Share News (FUM)

Share Price Information for Futura Medical (FUM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 40.70
Bid: 40.10
Ask: 40.95
Change: -0.60 (-1.45%)
Spread: 0.85 (2.12%)
Open: 41.30
High: 41.30
Low: 40.60
Prev. Close: 41.30
FUM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET CLOSE: BP and Prudential help snap FTSE losing streak

Tue, 06th Feb 2024 17:04

(Alliance News) - Stock prices in London pushed higher on Tuesday, with the FTSE 100 registering its first rise in four trading days, with oil major BP the star performer.

The FTSE 100 index ended up 68.15 points, 0.9%, at 7,681.01. London's large-cap index was on a four-day losing streak ahead of Tuesday's session.

The FTSE 250 ended 152.79 points higher, 0.8%, at 19,171.34, and the AIM All-Share rose 3.80 points, 0.5%, at 754.17.

The Cboe UK 100 shot up 1.1% at 769.35, the Cboe UK 250 added 1.0% at 16,613.67, but the Cboe Small Companies faded 0.3% to 14,638.59.

In mainland Europe, the CAC 40 in Paris rose 0.7%, while the DAX 40 in Frankfurt climbed 0.7%.

In New York, the Dow Jones Industrial Average was up 0.2% at the time of the closing bell in Europe. The S&P 500 was only marginally higher, while the Nasdaq Composite was a touch lower.

The European open received some impetus after bullish trade in Asia, on policy support measures to boost beleaguered shares. Stocks exposed to China were among the better performers in London, with Asia-focused insurer Prudential up 3.8%.

There was also some better data which bolstered sentiment in Europe. The European Central Bank said that median expectations for inflation over the next 12 months decreased as it published a consumer expectation survey from December.

Median expectations for inflation over the next 12 months eased to 3.2% in December from 3.5% in November. The ECB said that this was the third consecutive month of decline.

Meanwhile, new manufacturing orders in Germany unexpectedly rose in December, according to preliminary data, marking an improvement from the previous month for Europe's largest economy.

According to Destatis, factory orders rose by 8.9% on-month in December, after being stagnant from October to November. FXStreet were expecting factory orders to be stagnant.

In the UK, the downturn in the construction sector eased slightly at the start of the year, according to a survey.

The S&P Global UK construction purchasing managers' index rose to 48.8 points in January from 46.8 points in December. This marks the highest reading since August 2023 and is higher than FXStreet market consensus of 47.3 points.

That said, the index remained below the crucial 50.0 no-change threshold for the fifth month running.

The pound was quoted at USD1.2590 late Tuesday in London, higher compared to USD1.2527 at the equities close on Monday. The euro stood at USD1.0749, up slightly against USD1.0728. Against the yen, the dollar was trading at JPY148.09, lower compared to JPY148.80.

In London, BP shares shot up 5.3%.

XTB analyst Kathleen Brooks commented: "Although 2023 full year profits were shy of estimates, the strong Q4 performance suggests that the company gathered steam at the end of last year, which is a good backdrop for 2024's performance. There was good news on gas trading and its profitable convenience line, which saw gross margins soar, the company also jumped on the AI bandwagon."

BP said it completed its USD1.5 billion share buyback on Friday, and now intends to initiate a new USD1.75 billion buyback, prior to reporting its first quarter results which are due on May 7. It intends to buy back USD3.5 billion in shares for the first half of 2024.

BP added that it plans to conduct share buybacks worth at least USD14 billion through 2025, as part of its commitment to return at least 80% of surplus cash flow to shareholders.

In 2023, revenue dropped by 14% to USD213.03 billion from USD248.89 billion in 2022. However, pretax profit jumped by 54% to USD23.75 billion from USD15.41 billion.

Renishaw surged 16%.

The Gloucestershire, England-based provider of manufacturing technologies, analytical instruments and medical devices said pretax profit fell 27% to GBP56.5 million in the six months that ended December 31 from GBP77.8 million a year before.

Revenue declined 4.9% to GBP330.5 million from GBP347.7 million a year earlier.

Despite the weaker results, Renishaw left its dividend unchanged at 16.8 pence per share.

Looking ahead, Chief Executive Officer William Lee said: "We expect an improvement in our trading performance in the second half of the financial year as market conditions improve, and as we continue to pursue a range of growth opportunities. To support our through-cycle growth strategy, we are continuing to focus on productivity and to make targeted investments in our people, our production facilities, and our new product pipeline."

Elsewhere in London, Futura Medical shares jumped 40% as it hailed its first "meaningful" from product sales.

The Guildford, Surrey-based pharmaceutical company expects to report GBP3.1 million revenue for 2023. No revenue was recognised in 2022.

Chief Executive Officer James Barder said: "I am incredibly proud to report that we have delivered on the three key objectives that we set out in 2023: achieving regulatory approval in the US; progressing commercial discussions by securing a standout distribution partner in Haleon for the largest consumer healthcare market in the world and reporting our first meaningful revenues. The delivery of this progress, alongside the fact that we have an award-winning product, has given us a robust and broad platform to build upon in the year ahead."

Aston Martin Lagonda shares fell 3.9%.

News of seven-time Formula One world champion Lewis Hamilton's switch to Ferrari from Mercedes dominated automotive space chatter last week. Aston Martin Lagonda, is sizing up a personnel change of its own, according to Bloomberg.

A Bloomberg report said Executive Chair Lawrence Stroll has contacted current and former heads of other luxury auto manufacturers to gauge interest in the role, citing people familiar with the matter.

It would mark the fourth change in CEO at the luxury car manufacturer in as many years.

Stroll tapped Felisa, formerly the boss of Ferrari between 2008 and 2016, to be CEO in May 2022. He replaced former Mercedes-AMG boss Tobias Moers, who spent less than two years in the job. His predecessor, Andy Palmer, left months after Stroll rescued Aston Martin in early 2020.

Brent oil was quoted at USD78.57 a barrel at the time of the London equities close on Tuesday, up from USD77.11 late Monday. Gold traded at USD2,036.43 an ounce against USD2,019.86.

Wednesday's economic calendar has a Halifax UK house price index reading and German industrial production data at 0700 GMT.

In the local corporate calendar, housebuilder Barratt Developments and emerging markets-focused asset manager Ashmore release half-year results. Packaging firm Smurfit Kappa reports annual results.

By Eric Cunha, Alliance News news editor

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
26 Apr 2022 18:03

TRADING UPDATES: Billington faces headwinds; Immotion plans spin-off

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
23 Mar 2022 15:35

Futura signs up Korean partner for erection gel product

(Sharecast News) - Pharmaceutical and drug delivery technology developer Futura Medical has entered into a licensing agreement with Menarini Korea, it announced on Wednesday, for the exclusive rights to commercialise the company's topical gel-based erectile dysfunction treatment MED3000 in South Korea.

Read more
23 Mar 2022 11:50

Futura Medical shares rise on licensing deal with Menarini Korea

(Alliance News) - Futura Medical PLC shares jumped on Wednesday after the company said it has entered a licensing agreement with A Menarini Korea Ltd or the exclusive rights to commercialise its MED3000 treatment in South Korea.

Read more
20 Dec 2021 21:59

TRADING UPDATES: Silver Bullet faces cyber attack; Zoltav to delist

TRADING UPDATES: Silver Bullet faces cyber attack; Zoltav to delist

Read more
20 Dec 2021 10:46

Futura Medical makes good progress with topical erection gel treatment

(Sharecast News) - Futura Medical updated the market on regulatory and commercial progress for 'MED3000', its topical gel formulation for the treatment of erectile dysfunction, on Monday.

Read more
29 Oct 2021 15:57

EXECUTIVE CHANGES: TP chair resigns amid pressure from Science Group

EXECUTIVE CHANGES: TP chair resigns amid pressure from Science Group

Read more
8 Oct 2021 13:51

EXECUTIVE CHANGES: WH Ireland hires new CFO; Grubhub founder exits JET

EXECUTIVE CHANGES: WH Ireland hires new CFO; Grubhub founder exits JET

Read more
29 Sep 2021 13:22

EARNINGS UPDATES: Pittards swings to profit; Immupharma loss widens

EARNINGS UPDATES: Pittards swings to profit; Immupharma loss widens

Read more
27 Sep 2021 16:54

Futura Medical inks licensing deal with Labtec Pharma

(Sharecast News) - Transdermal drug delivery technology company Futura Medical has entered into a licensing agreement with Labatec Pharma, a Switzerland-based specialty pharma company focussed on commercialisation in the Europe and Middle East and North Africa (MENA) regions, it announced on Monday.

Read more
27 Sep 2021 12:01

IN BRIEF: Futura Medical teams with Labatec to commercialise MED3000

IN BRIEF: Futura Medical teams with Labatec to commercialise MED3000

Read more
22 Sep 2021 17:53

UK earnings, trading statements calendar - next 7 days

UK earnings, trading statements calendar - next 7 days

Read more
15 Sep 2021 20:23

IN BRIEF: Futura progressing US regulatory submission for MED3000

IN BRIEF: Futura progressing US regulatory submission for MED3000

Read more
1 Sep 2021 20:56

TRADING UPDATES: Sanderson Selfridges deal; Cazoo ups Forward Partners

TRADING UPDATES: Sanderson Selfridges deal; Cazoo ups Forward Partners

Read more
31 Aug 2021 15:08

Futura enters erection gel licensing deal with M8

(Sharecast News) - Futura Medical has entered into a licensing agreement with M8 Pharmaceuticals, a specialty biopharmaceutical company focused on commercialisation in Latin America, for the rights to exclusively develop and commercialise its topical, gel-based erectile dysfunction (ED) treatment MED3000 in Brazil and Mexico, it announced on Tuesday.

Read more
19 Jul 2021 19:13

TRADING UPDATES: Sareum raises GBP1 million; Marlowe buys Core Stream

TRADING UPDATES: Sareum raises GBP1 million; Marlowe buys Core Stream

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.